Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biofermin (Bifidobacteria) for gastrointestinal symptoms in type 2 diabetes mellitus
jRCTs051190109Completed
- Sponsor
- Biofermin Pharmaceutical
- Start
- Apr 2020
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Lactasin in type 2 diabetes mellitus (T2DM), sponsored by Biofermin Pharmaceutical. Started Apr 2020; status: completed.
02
Drugs
Lactasin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051190109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190109.